Loading
JS105 is an experimental small-molecule drug from Risen (Suzhou) Pharma Tech in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.
JS105 is a small-molecule drug developed by Risen (Suzhou) Pharma Tech. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Patients will receive oral JS105 on Days 1-28 of each 4-week cycle. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07207070 (A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer), in HR-positive / HER2-negative breast cancer. The largest, NCT07207070, plans to enrol 312 participants with primary completion expected 2029-05-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.JS105 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"JS105" OR ABSTRACT:"JS105") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JS105, not a curated reading list.
Shares Shanghai Junshi Biosciences and the tag pipeline.
Shares A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors, Shanghai Junshi Biosciences and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.